Scholars@Duke

RAS blocker effects on first HF hospitalization or CV death does not differ in Black and non-Black patients with HFrEF.

Publication ,  Journal Article
Rambarat, P; Newby, LK
Published in: Ann Intern Med
October 2024
Published version (DOI) Link to item

Shen L, Lee MMY, Jhund PS, et al. Revisiting race and the benefit of RAS blockade in heart failure: a meta-analysis of randomized clinical trials. JAMA. 2024;331:2094-2104. 38809561.

Duke Scholars

Laura Kristin Newby
Author Laura Kristin Newby Medicine, Cardiology

Published In

Ann Intern Med

DOI

10.7326/ANNALS-24-02170-JC

EISSN

1539-3704

Publication Date

October 2024

Volume

177

Issue

10

Start / End Page

JC112

Location

United States

Related Subject Headings

  • General & Internal Medicine
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rambarat, P., & Newby, L. K. (2024). RAS blocker effects on first HF hospitalization or CV death does not differ in Black and non-Black patients with HFrEF. Ann Intern Med, 177(10), JC112. https://doi.org/10.7326/ANNALS-24-02170-JC
Rambarat, Paula, and L Kristin Newby. “RAS blocker effects on first HF hospitalization or CV death does not differ in Black and non-Black patients with HFrEF.” Ann Intern Med 177, no. 10 (October 2024): JC112. https://doi.org/10.7326/ANNALS-24-02170-JC.
Rambarat, Paula, and L. Kristin Newby. “RAS blocker effects on first HF hospitalization or CV death does not differ in Black and non-Black patients with HFrEF.” Ann Intern Med, vol. 177, no. 10, Oct. 2024, p. JC112. Pubmed, doi:10.7326/ANNALS-24-02170-JC.

Published In

Ann Intern Med

DOI

10.7326/ANNALS-24-02170-JC

EISSN

1539-3704

Publication Date

October 2024

Volume

177

Issue

10

Start / End Page

JC112

Location

United States

Related Subject Headings

  • General & Internal Medicine
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences